Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023)

Avalo Therapeutics (AVTX) posted Current Deferred Revenue of $111000.0 for Q1 2023, up 26.14% on a QoQ basis from $88000.0 in Q4 2022.

Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023) Analysis & Trends

Avalo Therapeutics' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $111000.0 for Q1 2023.

Quarterly Current Deferred Revenue changed N/A year-over-year to $111000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $111000.0 (changed N/A YoY) and the FY2022 annual result came in at $88000.0, changed N/A from the prior year.
Current Deferred Revenue was $111000.0 for Q1 2023 at Avalo Therapeutics, up from $88000.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $442000.0 in Q3 2022 and bottomed at $88000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Avalo Therapeutics	1.04 Mn	1.04 Mn	-

Download Data